Incannex Healthcare Inc. (Nasdaq: IXHL) announced that it has raised $12.5 million to fund ongoing clinical trials. Incannex said the studies include completing the U.S. Phase 2 study of IHL-42X, an oral, once-daily treatment for sleep apnea, and its expansion into the Phase 3 portion of the study, with…
Please login to read all 415 words.
